targeted protein degradation

Lucid Diligence Brief - BioPharma

Nurix Roche Bexobrutideg Deal | Lucid Diligence Brief

Roche’s collaboration with Nurix turns bexobrutideg into a multi-indication BTK…

by Marione Briones

Hematology

Hematology Today—June 2, 2026

This week’s Hematology update highlights ASCO 2026 readouts, regulatory…

by LucidQuest

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: PAQ Therapeutics Series B for PT0511 pan-KRAS degrader

Lucid Diligence Brief: PAQ Therapeutics Series B for PT0511 pan-KRAS degrader…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics

Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics Professional…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Triana Biomedicines $120M Series B for TRI-611 in ALK+ NSCLC

Lucid Diligence Brief: Triana Biomedicines $120M Series B for TRI-611 in ALK+…

by Timos Papagatsias

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required
You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.